Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires constant protein replacement therapy. Reviewed herein are the current state in the manufacturing of FIX, improved variants of the recombinant protein for therapy, transgenic organisms for obtaining FIX, and the advances in the gene therapy of hemophilia B.
CITATION STYLE
Orlova, N. A., Kovnir, S. V., Vorobiev, I. I., & Gabibov, A. G. (2012). Coagulation Factor IX for Hemophilia B Therapy. Acta Naturae, 4(2), 62–73. https://doi.org/10.32607/20758251-2012-4-2-62-73
Mendeley helps you to discover research relevant for your work.